Purple Biotech (PPBT)
NASDAQ:PPBT
Want to see PPBT full AI Analyst Report?
Top Page
Purple Biotech
(NASDAQ:PPBT)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-69.20% Downside)
Action:Reiterated
Date:06/12/26
The score is driven primarily by very weak financial performance (no meaningful revenue, large recurring losses, and ongoing cash burn, despite low leverage). Technicals add further pressure with the price far below key moving averages and negative momentum indicators. Valuation is also constrained by a negative P/E and no dividend yield support.
Positive Factors
Differentiated CAPTN-3 platform & IM1240 preclinical data
Robust preclinical efficacy and a capping design that materially improves PK and reduces cytokine release address core safety and exposure challenges for T-cell engagers. This structural advantage can widen the therapeutic window, improve clinical success odds, and make CAPTN-3 materially more partnerable over the next 2–6 months and beyond.
Negative Factors
Persistent negative cash generation
Sustained negative operating and free cash flows mean the company must rely on external funding to advance programs. Over 2–6 months this structural cash burn increases dilution and execution risk, constraining resources for IND-enabling work or expanding trials without partners or new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated CAPTN-3 platform & IM1240 preclinical data
Robust preclinical efficacy and a capping design that materially improves PK and reduces cytokine release address core safety and exposure challenges for T-cell engagers. This structural advantage can widen the therapeutic window, improve clinical success odds, and make CAPTN-3 materially more partnerable over the next 2–6 months and beyond.
Read all positive factors
Purple Biotech (PPBT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.98M
Dividend YieldN/A
Average Volume (3M)415.61K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue GrowthN/A
EPS Growth-33.12%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-9933.94
Shares Outstanding1,013,064
10 Day Avg. Volume296,099
30 Day Avg. Volume415,608
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.00
Enterprise Value/Ebitda0.47
Forecast
1Y Price Target
$30.00Price Target Upside516.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Purple Biotech Business Overview & Revenue Model
Company Description
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline ...
How the Company Makes Money
Purple Biotech’s business model is centered on monetizing its drug-development pipeline through a combination of (1) collaboration and licensing arrangements and (2) potential future product sales if any candidates receive regulatory approval. His...
Purple Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 195.80K | 0.00 | 0.00 |
| Gross Profit | -224.44K | 0.00 | -186.00K | -196.00 | -120.00 | -55.00 |
| EBITDA | -7.64M | -26.25M | -7.05M | -19.88M | -21.49M | -17.52M |
| Net Income | -26.20M | -26.39M | -7.24M | -19.88K | -21.67M | -18.38M |
Balance Sheet | ||||||
| Total Assets | 14.42M | 17.57M | 37.04M | 44.30M | 54.62M | 70.20M |
| Cash, Cash Equivalents and Short-Term Investments | 6.43M | 9.57M | 8.52M | 15.41M | 32.11M | 47.20M |
| Total Debt | 184.00K | 244.00K | 183.00K | 351.00K | 515.00K | 749.00K |
| Total Liabilities | 4.75M | 7.91M | 4.13M | 10.01M | 7.52M | 5.09M |
| Stockholders Equity | 9.72M | 9.71M | 32.86M | 34.21M | 46.91M | 64.83M |
Cash Flow | ||||||
| Free Cash Flow | -4.67M | -5.54M | -14.37M | -19.93M | -16.96M | -15.19M |
| Operating Cash Flow | -6.71M | -5.54M | -14.37M | -19.93M | -16.73M | -15.07M |
| Investing Cash Flow | 320.34K | 449.54K | 509.00K | 13.88M | 19.91M | 13.41M |
| Financing Cash Flow | 6.21M | 6.41M | 6.77M | 5.45M | 1.11M | 1.51M |
Purple Biotech Technical Analysis
Negative
4.87
Price Trends
3.67
Negative
4.34
Negative
5.85
Negative
Market Momentum
-0.48
Positive
24.95
Positive
9.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPBT, the sentiment is Negative. The current price of 4.87 is above the 20-day moving average (MA) of 2.81, above the 50-day MA of 3.67, and below the 200-day MA of 5.85, indicating a bearish trend. The MACD of -0.48 indicates Positive momentum. The RSI at 24.95 is Positive, neither overbought nor oversold. The STOCH value of 9.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PPBT.
Purple Biotech Risk Analysis
Purple Biotech disclosed 77 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Purple Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $6.98M | -0.24 | -10.00% | ― | ― | -33.12% | |
| ― | $5.52M | -1.08 | -165.94% | ― | -70.00% | 14.70% | |
| ― | $2.80M | -0.27 | -168.95% | ― | ― | 84.00% | |
41 Neutral | $48.89M | -1.09 | -1335.64% | ― | ― | 66.47% |
* Healthcare Sector Average
PPBT
Purple Biotech
1.64
-22.96
-93.33%
TCRT
Alaunos Therapeutics
2.24
-1.42
-38.80%
OGEN
Oragenics
0.61
-3.76
-86.04%
PMCB
PharmaCyte Biotech
0.83
-0.23
-21.89%
KALA
KALA BIO
3.14
-205.86
-98.50%
Purple Biotech Corporate Events
Purple Biotech Unveils IM1240 Preclinical Data at EACR 2026, Validating CAPTN-3 Immunotherapy Platform
Jun 11, 2026
Purple Biotech on June 11, 2026 reported new preclinical data for its lead CAPTN-3 candidate IM1240, presented at the EACR 2026 congress in Budapest, that underscore strong anti-tumor activity in patient-derived, PD-1- and chemotherapy-resistant h...
Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum
May 15, 2026
On May 15, 2026, Purple Biotech reported first-quarter 2026 results and highlighted progress on its CAPTN-3 tri-specific antibody platform, including new preclinical data showing potent anti-tumor activity of lead candidate IM1240 in treatment-res...
Purple Biotech Unveils Promising IM1240 Preclinical Data From CAPTN-3 Immunotherapy Platform
Apr 27, 2026
On April 27, 2026, Purple Biotech reported new preclinical data for IM1240, the lead tri-specific antibody from its CAPTN-3 platform, showing potent anti-tumor activity in all seven tested treatment-resistant patient-derived tumor samples, includi...
Purple Biotech Forms Scientific Advisory Board to Drive CAPTN-3 Tri-Specific Antibody Platform
Apr 23, 2026
On April 23, 2026, Purple Biotech announced it has established a Scientific Advisory Board made up of leading experts in T-cell and NK-cell biology, tumor immunology, and clinical oncology to guide development of its CAPTN-3 tri-specific antibody ...
Purple Biotech Taps Converge Bio’s AI to Turbocharge Tri-Specific Antibody Platform
Mar 25, 2026
On March 25, 2026, Purple Biotech announced a collaboration with Boston-based Converge Bio to apply generative AI to the design and optimization of its next-generation tri-specific antibody platform for solid tumors. The partnership builds on prio...
Purple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones
Mar 19, 2026
Purple Biotech on March 18, 2026 reported that it has issued an updated March 2026 corporate presentation outlining progress across its immuno-oncology pipeline and platform. The company highlighted its CAPTN-3 conditionally activated tri-specific...
Purple Biotech Regains Nasdaq Compliance on Minimum Bid Price
Mar 17, 2026
On March 17, 2026, Purple Biotech announced it had regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company satisfied Nasdaq Listing Rule 5550(a)(2) after its American De...
Purple Biotech Posts 2025 Loss, Doubles Down on CAPTN-3 Immunotherapy Platform
Mar 13, 2026
On March 13, 2026, Israel-based Purple Biotech reported fourth-quarter and full-year 2025 results that underscored a strategic pivot toward its CAPTN-3 tri-specific antibody platform, advancing lead candidate IM1240 and naming IM1305 as a second d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.